The Patent Battle of COVID-19 Vaccines

The research and development and production of drugs and vaccines has always been a competitive field, and patent rights are the key in this field. The recent series of patent disputes, especially involvingCOVID-19The disputes over vaccines and related technologies have aroused widespread concern. These disputes reflect the wrestling between pharmaceutical companies in the field of patents, aiming to protect their intellectual property rights and market share. It is worth mentioning that these patent disputes not only involveCOVID-19Vaccines are also involved in patent rights in other areas. Many pharmaceutical companies are struggling to protect their innovation and intellectual property rights to ensure that they gain a competitive advantage in the market.

For many large pharmaceutical companies,2021Sales in the first quarter of the year were somewhat disappointing, but not for Pfizer, which wasCOVID-19 ComirnatyThe vaccine has grown almost geometrically, and this vaccine has been used in digital codes.BNT162b2And famous.

this well-knownmRNAVaccines-ComirnatyVaccines, in2021Sales revenue for the first three months of the year reached35Billions of dollars, and in2021In the first half of the year, Pfizer raised its annual sales forecast110Billions of dollars, expectedupTo260billion, sales rose in the second quarter92%Therefore, it is estimated that this is the most popularCOVIDVaccines should account for US pharmaceutical giant's annual sales36％。

Comirnatydid make a significant contribution to Pfizer's growth, with the third quarterCOVID-19Vaccines take up a share of Pfizer's revenue41%(over330Billion US dollars), this is not the limit, Pfizer has recently increased itsmRNAPrices of vaccines in European countries.

In the context of all this, people have all but forgotten that Pfizer and the European Union are concerned aboutBioNTechThe previous transaction for the supply of vaccines, which involved the supply18The deal adds a thick financial icing to the huge cake baked by the U.S. pharmaceutical giant Pfizer, which, according to analysts' preliminary estimates, was made by Pfizer in this major deal./BioNTechVaccines manufactured in each dose15.5The euro was sold at a sky-high price, according to their data, as of that time, in the form of free cash flow.200billion dollars,

Increased sales700Billion US dollars, reached by the end of the year700Billions of dollars.

while in2023Biotechnology companies associated with well-known academic institutionsPromosomeAllegationsModerna,PfizerandBioNTechviolatedmRNAtechnology-related patents,PromosomeWith the Scripps Institute accusing the world-renownedCOVID mRNAVaccine makers have replicated a technology that makes it possible to deliver small enough doses in vaccines.mRNAto achieve its safe and effective use in litigation,PromosomeRequirements fromCOVID mRNAVaccines gain their share in sales, as is known, these vaccines have become a great success, according to reports,2022Pfizer recified378billion dollars in sales, whileModernaobtained184billion dollars in sales.

At the same time, inCOVID mRNAControversy over the use of lipid nanoparticle technology in vaccines has almost become a tradition, yet new vaccines have emerged and new patent disputes have erupted, as has2023year,GSKSue Pfizer, dispute over respiratory syncytial virus (RSV) patent rights for vaccines,GSKClaims that Pfizer producesAbrysvowhen violated.GSKFour about2013launched inArexvypatents for vaccines, in a copy of the complaint states that Pfizer'sGSKAfter a few years to start research and developmentRSVThe vaccine, andAbrysvo"Violated.GSKone or more patent applications", respectively, the No.8 563 002,11 261 239,11 629 181and11 655 284According to the British, the American competitor did not start research and development until seven years later.Abrysvoand may have usedGSKtechnology, the complaint claims that Pfizer at least from2019Year10I knew it from month to month.GSKpatented technology and attempted to challenge the validity of two European patents.

In short, patent battles continue to be fierce among global pharmaceutical companies, involving the relevant patent rights and interests of many companies. These disputes not only affect the profitability of the company, but also may have a profound impact on future pharmaceutical innovation and vaccine research and development. Therefore, the protection of patent rights and dispute settlement will continue to be an important issue in the pharmaceutical industry.